Metsera reports Q1 EPS ($1.03) vs. ($1.44) last year

“The first quarter of 2025 was a period of focused execution and acceleration at Metsera (MTSR),” said Whit Bernard, Chief Executive Officer of Metsera. “We remain on track to deliver on all of our committed clinical milestones for 2025, including five-week data for our ultra-long acting amylin analog MET-233i in Q2, 28-week data for our ultra-long acting GLP-1 RA MET-097i by mid-year, and multiple additional clinical readouts of our injectable and oral programs by year-end.”